Lataa...
Response to post-axitinib treatment in patients with metastatic renal cell carcinoma
BACKGROUND: Axitinib is a potent inhibitor of the vascular endothelial growth factor (VEGF) receptor family with clinical activity in patients with metastatic renal cell carcinoma (mRCC). Given this biochemical potency, the clinical activity of subsequent treatment with targeted therapies in patient...
Tallennettuna:
| Julkaisussa: | BMC Cancer |
|---|---|
| Päätekijät: | , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4810513/ https://ncbi.nlm.nih.gov/pubmed/27026229 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2282-5 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|